Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomically Selected FOLFOX in Gastric and GEJ Tumors
NCT00514020Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2007
- Primary completion
- Jan 2011
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, oxaliplatin, folinic acid in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Vanderbilt-Ingram Cancer Center. Started Aug 2007; status: completed.
02
Drugs
fluorouraciloxaliplatinfolinic acid
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00514020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514020.